April 18, 2018 / 11:12 AM / 8 months ago

BRIEF-Synlogic Doses First Subject In Phase 1/2A Trial Of Synb1618 For Treatment Of Phenylketonuria

April 18 (Reuters) - Synlogic Inc:

* SYNLOGIC DOSES FIRST SUBJECT IN PHASE 1/2A TRIAL OF SYNB1618 FOR TREATMENT OF PHENYLKETONURIA

* SYNLOGIC INC - SECOND SYNTHETIC BIOTIC PROGRAM TO MOVE INTO CLINICAL STUDIES IN 2018

* SYNLOGIC INC - INTERIM DATA FROM SYNB1618 STUDY EXPECTED IN 2018; FULL DATA IN 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below